Tags

Type your tag names separated by a space and hit enter

Comparison of epidural anaesthesia with ropivacaine 0.5% and bupivacaine 0.5% for caesarean section.
Can J Anaesth. 1998 Nov; 45(11):1066-71.CJ

Abstract

PURPOSE

To compare ropivacaine 0.5% with bupivacaine 0.5% for epidural anaesthesia for Caesarean section.

METHODS

Healthy pregnant women, scheduled for elective Caesarean section were enrolled into this randomized, double-blind, parallel-group study. Epidural block was obtained with 20-30 ml of ropivacaine (group R) or bupivacaine (group B) and surgery started when anaesthesia was reached T6. Maternal heart rate and blood pressure and fetal heart rate were assessed before the test dose and at five minute intervals until the end of surgery. At the same intervals, sensory and motor block characteristics were determined. Apgar scores and Neurologic and Adaptive Capacity Scores (NACS) were determined after delivery. Adverse events were recorded.

RESULTS

Sixty-five patients were enrolled and data from 61 were available for analysis; 30 ropivacaine and 31 bupivacaine. Time from the end of the last injection to the start of surgery was 46 +/- 13 min (mean +/- SD) in gp R and 53 +/- 25 min in gp B (P:NS). The median duration of analgesia varied between 1.7 and 4.2 hr in gp R and between 1.8 and 4.4 hr in gp B (P:NS). In patients who developed Bromage 4 block, it persisted longer in those in gp B (2.5 hr) than in gp R (0.9 hr) (P < 0.05). The quality of analgesia was satisfactory in 27/29 patients (93%) in gp R and 27/31 patients (87%) in gp B (P:NS), although supplemental i.v. opioid was required in ten and seven patients, respectively. The most common adverse events in the mother were hypotension (63% gp R and 61% in gp B) (NS) and nausea (30% and 58%, in group R and B, respectively) (P = 0.05). Apgar scores were 7 after five minutes in all neonates.

CONCLUSION

Ropivacaine 0.5% and bupivacaine 0.5% provided effective epidural anaesthesia for Caesarean section although supplementation with i.v. opioid was commonly required.

Authors+Show Affiliations

Department of Anaesthesia, University of Ottawa, Ontario. ecrosby@fox.nstn.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10021954

Citation

Crosby, E, et al. "Comparison of Epidural Anaesthesia With Ropivacaine 0.5% and Bupivacaine 0.5% for Caesarean Section." Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie, vol. 45, no. 11, 1998, pp. 1066-71.
Crosby E, Sandler A, Finucane B, et al. Comparison of epidural anaesthesia with ropivacaine 0.5% and bupivacaine 0.5% for caesarean section. Can J Anaesth. 1998;45(11):1066-71.
Crosby, E., Sandler, A., Finucane, B., Writer, D., Reid, D., McKenna, J., Friedlander, M., Miller, A., O'Callaghan-Enright, S., Muir, H., & Shukla, R. (1998). Comparison of epidural anaesthesia with ropivacaine 0.5% and bupivacaine 0.5% for caesarean section. Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie, 45(11), 1066-71.
Crosby E, et al. Comparison of Epidural Anaesthesia With Ropivacaine 0.5% and Bupivacaine 0.5% for Caesarean Section. Can J Anaesth. 1998;45(11):1066-71. PubMed PMID: 10021954.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of epidural anaesthesia with ropivacaine 0.5% and bupivacaine 0.5% for caesarean section. AU - Crosby,E, AU - Sandler,A, AU - Finucane,B, AU - Writer,D, AU - Reid,D, AU - McKenna,J, AU - Friedlander,M, AU - Miller,A, AU - O'Callaghan-Enright,S, AU - Muir,H, AU - Shukla,R, PY - 1999/2/18/pubmed PY - 1999/2/18/medline PY - 1999/2/18/entrez SP - 1066 EP - 71 JF - Canadian journal of anaesthesia = Journal canadien d'anesthesie JO - Can J Anaesth VL - 45 IS - 11 N2 - PURPOSE: To compare ropivacaine 0.5% with bupivacaine 0.5% for epidural anaesthesia for Caesarean section. METHODS: Healthy pregnant women, scheduled for elective Caesarean section were enrolled into this randomized, double-blind, parallel-group study. Epidural block was obtained with 20-30 ml of ropivacaine (group R) or bupivacaine (group B) and surgery started when anaesthesia was reached T6. Maternal heart rate and blood pressure and fetal heart rate were assessed before the test dose and at five minute intervals until the end of surgery. At the same intervals, sensory and motor block characteristics were determined. Apgar scores and Neurologic and Adaptive Capacity Scores (NACS) were determined after delivery. Adverse events were recorded. RESULTS: Sixty-five patients were enrolled and data from 61 were available for analysis; 30 ropivacaine and 31 bupivacaine. Time from the end of the last injection to the start of surgery was 46 +/- 13 min (mean +/- SD) in gp R and 53 +/- 25 min in gp B (P:NS). The median duration of analgesia varied between 1.7 and 4.2 hr in gp R and between 1.8 and 4.4 hr in gp B (P:NS). In patients who developed Bromage 4 block, it persisted longer in those in gp B (2.5 hr) than in gp R (0.9 hr) (P < 0.05). The quality of analgesia was satisfactory in 27/29 patients (93%) in gp R and 27/31 patients (87%) in gp B (P:NS), although supplemental i.v. opioid was required in ten and seven patients, respectively. The most common adverse events in the mother were hypotension (63% gp R and 61% in gp B) (NS) and nausea (30% and 58%, in group R and B, respectively) (P = 0.05). Apgar scores were 7 after five minutes in all neonates. CONCLUSION: Ropivacaine 0.5% and bupivacaine 0.5% provided effective epidural anaesthesia for Caesarean section although supplementation with i.v. opioid was commonly required. SN - 0832-610X UR - https://www.unboundmedicine.com/medline/citation/10021954/Comparison_of_epidural_anaesthesia_with_ropivacaine_0_5_and_bupivacaine_0_5_for_caesarean_section_ L2 - https://doi.org/10.1007/BF03012393 DB - PRIME DP - Unbound Medicine ER -